B-cell acute lymphoblastic leukemia (B-ALL) is a cancer of the blood and bone marrow in which immature white blood cells, called B lymphoblasts, multiply uncontrollably and crowd out healthy blood cells. It is the most common childhood cancer, though it also affects adults. Long-term survival reaches 80% to 90% in children but drops to 40% to 50% in adults, depending on genetic features and how quickly the disease responds to treatment.
How B-ALL Develops in the Bone Marrow
Your bone marrow constantly produces new blood cells from immature stem cells. In normal development, some of these stem cells mature into B lymphocytes, a type of white blood cell that helps fight infections. In B-ALL, something goes wrong early in that process. Immature blood-forming cells acquire genetic damage that freezes them at an early stage of development, before they can become functioning B cells. These stuck, immature cells then begin multiplying rapidly.
As these leukemia cells, called blasts, accumulate in the bone marrow, they physically displace the cells responsible for making red blood cells, platelets, and healthy white blood cells. That crowding effect is what produces most of the symptoms people experience. Research suggests the initial genetic damage can sometimes occur before birth, in blood-forming cells in the fetal liver, though additional mutations acquired later are usually needed to trigger full-blown leukemia.
Common Symptoms
Because B-ALL disrupts normal blood cell production, symptoms reflect the shortage of each cell type. Low red blood cells cause pale skin, fatigue, weakness, and shortness of breath. Low platelets lead to easy bruising, bleeding gums, and frequent or severe nosebleeds. And a lack of functional white blood cells leaves you vulnerable to frequent infections, often accompanied by fevers that don’t resolve.
Many people also experience bone pain, particularly in the long bones of the arms and legs, caused by the expanding mass of leukemia cells inside the marrow. Swollen lymph nodes may appear as painless lumps in the neck, armpits, abdomen, or groin. These symptoms often develop over days to weeks rather than months, which is one reason doctors treat B-ALL as a medical urgency once suspected.
How B-ALL Is Diagnosed
Diagnosis starts with blood tests that reveal abnormal cell counts, but confirmation requires a bone marrow biopsy. A sample of marrow is examined under a microscope and through specialized lab techniques. B-ALL is formally diagnosed when 20% or more of the cells in the bone marrow are lymphoid blasts.
To confirm the blasts are specifically B-cell in origin, pathologists use a technique called flow cytometry, which identifies proteins on the surface of the leukemia cells. The most important marker is CD19, a protein found on nearly every B-ALL case and central to both initial diagnosis and long-term monitoring. Other key markers include CD10, which helps classify the specific subtype, and CD22, which appears very early in B-cell development. The combination of these surface proteins distinguishes B-ALL from T-cell leukemia and other blood cancers.
Genetics That Shape the Outlook
Not all B-ALL is the same. The specific chromosomal abnormalities inside the leukemia cells heavily influence both prognosis and treatment decisions. Two genetic changes illustrate this range clearly.
A fusion between genes on chromosomes 12 and 21 (called ETV6::RUNX1) is one of the most common findings, present in roughly 27% of standard-risk pediatric cases. It is associated with favorable survival rates, though outcomes still depend on how quickly the disease responds to initial treatment and the patient’s age and white blood cell count at diagnosis.
On the other end of the spectrum, a fusion between chromosomes 9 and 22, known as the Philadelphia chromosome, historically carried a very poor prognosis. This fusion produces an abnormal protein with overactive signaling that drives leukemia cell growth. The discovery of drugs that specifically block this protein transformed outcomes for these patients, turning what was once among the worst genetic findings into one that can be effectively targeted.
Other unfavorable features include rearrangements of the KMT2A gene, having fewer than 44 chromosomes per cell (hypodiploidy), and a specific amplification of the RUNX1 gene. Genetic testing at diagnosis is standard because these results directly determine how intensive treatment needs to be.
Treatment Phases
Treatment for B-ALL is a multi-year process built around chemotherapy delivered in three distinct phases. The entire course typically spans two to three years.
The first phase, called remission induction, aims to kill leukemia cells in the blood and bone marrow as rapidly as possible. This is the most intensive period, usually lasting four to six weeks, and the goal is to reach remission, defined as fewer than 5% blasts in the bone marrow with recovery of normal blood counts. Most patients achieve remission during this phase.
Consolidation therapy follows, targeting any leukemia cells that survived induction. Even when blasts are no longer visible under a microscope, residual disease can persist at levels only detectable by molecular testing. Consolidation uses additional rounds of chemotherapy to eliminate these hidden cells and prevent relapse.
The final phase, maintenance therapy, is a long stretch of lower-intensity treatment designed to keep the leukemia from returning. It is less physically grueling than the earlier phases and usually allows patients to resume more normal daily activities, though regular clinic visits and blood monitoring continue throughout.
Protecting the Brain and Spinal Cord
Leukemia cells can hide in the fluid surrounding the brain and spinal cord, where standard intravenous chemotherapy cannot easily reach. To prevent this, all B-ALL patients receive preventive treatment delivered directly into the spinal fluid during lumbar punctures. Most patients receive around eight doses spread across treatment, though those with Philadelphia chromosome-positive disease typically receive twelve, and certain aggressive subtypes may require sixteen. This approach has largely replaced the older practice of cranial radiation, which carried significant long-term side effects.
Targeted and Immune-Based Therapies
For patients whose leukemia returns after initial treatment or does not respond to chemotherapy, newer therapies have dramatically improved the chances of achieving a second remission.
One approach uses an antibody that simultaneously latches onto a protein on leukemia cells (CD19) and a protein on the patient’s own immune T cells, physically bringing them together so the T cells can destroy the cancer. This treatment has produced remission in over 30% of patients with relapsed or treatment-resistant disease. A second approach pairs an antibody targeting CD22 on leukemia cells with a potent chemotherapy payload, delivering the drug directly to the cancer. In a head-to-head trial, this strategy achieved remission in about 81% of patients, compared to roughly 30% with standard chemotherapy alone.
CAR T-cell therapy represents the most personalized option. In this process, a patient’s own T cells are collected, genetically engineered in a laboratory to recognize and attack CD19-bearing leukemia cells, and then infused back into the patient. Multiple CAR T-cell products are now approved. The most recently approved, in November 2024, is specifically for adults whose B-ALL has relapsed after a short remission, has not responded to two or more prior treatments, or has returned after a stem cell transplant. These therapies are reserved for patients who have exhausted other options, but they offer a meaningful chance of remission in situations where few alternatives exist.
Factors That Influence Survival
Age is the single most important dividing line in B-ALL outcomes. Children between ages one and nine with standard-risk features have the best prognosis, with long-term survival rates between 80% and 90%. Adults fare significantly worse, with five-year survival closer to 40% to 50%. This gap reflects both biological differences (adult B-ALL more frequently carries high-risk genetic changes) and the fact that younger patients tolerate intensive chemotherapy better.
Within any age group, the speed of initial response matters enormously. Patients who clear leukemia cells quickly during induction therapy consistently do better than those with slow early responses, regardless of their genetic profile. White blood cell count at diagnosis also plays a role: very high counts signal a larger burden of disease and are associated with higher-risk classification. These factors, combined with genetic testing, determine whether a patient receives standard or intensified therapy from the start.